178 related articles for article (PubMed ID: 6092781)
21. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor.
Santen RJ; Santner SJ; Tilsen-Mallett N; Rosen HR; Samojlik E; Veldhuis JD
Cancer Res; 1982 Aug; 42(8 Suppl):3353s-3359s. PubMed ID: 7083200
[TBL] [Abstract][Full Text] [Related]
22. Adrenal effects of low-dose aminoglutethimide when used alone in postmenopausal women with advanced breast cancer.
Carella MJ; Dimitrov NV; Gossain VV; Srivastava L; Rovner DR
Metabolism; 1994 Jun; 43(6):723-7. PubMed ID: 8201961
[TBL] [Abstract][Full Text] [Related]
23. Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
Höffken K; Kempf H; Miller AA; Miller B; Schmidt CG; Faber P; Kley HK
Cancer Treat Rep; 1986 Oct; 70(10):1153-7. PubMed ID: 3756937
[TBL] [Abstract][Full Text] [Related]
24. Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer.
Bruning PF; Bonfrer JM; Hart AA; van der Linden E; de Jong-Bakker M; Moolenaar AJ; Nooijen WJ
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):369-76. PubMed ID: 2702989
[TBL] [Abstract][Full Text] [Related]
25. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
Samojlik E; Santen RJ; Wells SA
J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399
[No Abstract] [Full Text] [Related]
26. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
27. Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients.
Geisler J; Lien EA; Ekse D; Lønning PE
J Steroid Biochem Mol Biol; 1997; 63(1-3):53-8. PubMed ID: 9449206
[TBL] [Abstract][Full Text] [Related]
28. Adrenal function under long-term raloxifene administration.
Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
30. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
[TBL] [Abstract][Full Text] [Related]
32. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
[TBL] [Abstract][Full Text] [Related]
33. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Santen RJ; Samojlik E; Lipton A; Harvey H; Ruby EB; Wells SA; Kendall J
Cancer; 1977 Jun; 39(6 Suppl):2948-58. PubMed ID: 194681
[TBL] [Abstract][Full Text] [Related]
34. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
MacNeill FA; Jones AL; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1992 Oct; 66(4):692-7. PubMed ID: 1419608
[TBL] [Abstract][Full Text] [Related]
35. Is aminoglutethimide an alternative to adrenalectomy for metastatic carcinoma of the breast?
Sterns EE; Bird CE; Mackie KW
Can J Surg; 1982 Nov; 25(6):695-7. PubMed ID: 7139430
[TBL] [Abstract][Full Text] [Related]
36. Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate S
Br J Cancer; 1983 Oct; 48(4):585-94. PubMed ID: 6684948
[TBL] [Abstract][Full Text] [Related]
37. Adrenal contribution to circulating estrogens in woman.
Wasada T; Akamine Y; Kato K; Ibayashi H; Nomura Y
Endocrinol Jpn; 1978 Apr; 25(2):123-8. PubMed ID: 208830
[TBL] [Abstract][Full Text] [Related]
38. Medical adrenalectomy and plasma steroids in advanced breast carcinoma.
Newsome HH; Brown PW; Terz JJ; Lawrence W
Surgery; 1978 Jan; 83(1):83-9. PubMed ID: 619476
[TBL] [Abstract][Full Text] [Related]
39. Effects of aminoglutethimide on delta 5-androstenediol metabolism in postmenopausal women with breast cancer.
Bird CE; Masters V; Sterns EE; Clark AF
Cancer Res; 1982 Nov; 42(11):4797-800. PubMed ID: 6290048
[TBL] [Abstract][Full Text] [Related]
40. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
